Format

Send to

Choose Destination
Scand J Infect Dis. 2013 Jul;45(7):567-9. doi: 10.3109/00365548.2012.752859. Epub 2012 Dec 28.

Cutaneous leishmaniasis in a patient receiving infliximab.

Author information

1
Department of Infectious Diseases, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. maliht_1@hotmail.com

Abstract

Leishmaniasis is endemic in the Mediterranean region, and the prevalence of latent infection in this area is high. Treatment with tumour necrosis factor (TNF) antagonists represents a major breakthrough in the treatment of several inflammatory diseases, including psoriasis. Reports describing opportunistic leishmaniasis in European patients treated with TNF-α antagonist drugs are rapidly accumulating. We describe a case of cutaneous leishmaniasis in a patient treated with infliximab and corticosteroids.

PMID:
23270475
DOI:
10.3109/00365548.2012.752859
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center